Cargando…

Computational Screening Strategy for Drug Repurposing Identified Niclosamide as Inhibitor of Vascular Calcification

Vascular calcification is a cardiovascular disorder with no therapeutic options. We recently reported that o-octanoyltransferase (CROT) suppression can inhibit vascular calcification in vivo and in vitro through amelioration of mitochondrial function and fatty acid metabolism. Inhibiting calcificati...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Takeshi, Asano, Takaharu, Okui, Takehito, Kuraoka, Shiori, Singh, Sasha A., Aikawa, Masanori, Aikawa, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811128/
https://www.ncbi.nlm.nih.gov/pubmed/35127876
http://dx.doi.org/10.3389/fcvm.2021.826529
_version_ 1784644362668343296
author Tanaka, Takeshi
Asano, Takaharu
Okui, Takehito
Kuraoka, Shiori
Singh, Sasha A.
Aikawa, Masanori
Aikawa, Elena
author_facet Tanaka, Takeshi
Asano, Takaharu
Okui, Takehito
Kuraoka, Shiori
Singh, Sasha A.
Aikawa, Masanori
Aikawa, Elena
author_sort Tanaka, Takeshi
collection PubMed
description Vascular calcification is a cardiovascular disorder with no therapeutic options. We recently reported that o-octanoyltransferase (CROT) suppression can inhibit vascular calcification in vivo and in vitro through amelioration of mitochondrial function and fatty acid metabolism. Inhibiting calcification with a small molecule compound targeting CROT-associated mechanisms will be a promising non-invasive treatment of vascular calcification. Here we used a computational approach to search for existing drugs that can inhibit vascular calcification through the CROT pathway. For screening of the compounds that reduce CROT expression, we utilized the Connectivity Map encompassing the L1000 computational platform that contains transcription profiles of various cell lines and perturbagens including small molecules. Small molecules (n = 13) were identified and tested in human primary smooth muscle cells cultured in osteogenic media to induce calcification. Niclosamide, an FDA-improved anthelmintic drug, markedly inhibited calcification along with reduced alkaline phosphatase activity and CROT mRNA expression. To validate this compound in vivo, LDL receptor (Ldlr)-deficient mice fed a high fat diet were given oral doses of niclosamide (0 or 750 ppm admixed with diet) for 10 weeks. Niclosamide treatment decreased aortic and carotid artery calcification as determined by optical near infrared molecular imaging (OsteoSense680) and histological analysis. In addition, niclosamide improved features of fatty liver, including decreased cholesterol levels along with decreased Crot expression, while plasma total cholesterol levels did not change. Proteomic analysis of aortic samples demonstrated that niclosamide affected wingless/integrated (Wnt) signaling pathway and decreased runt-related transcription factor 2 (Runx2) expression, an essential factor for calcification. Our target discovery strategy using a genetic perturbation database with existing drugs identified niclosamide, that in turn inhibited calcification in vivo and in vitro, indicating its potential for the treatment of vascular calcification.
format Online
Article
Text
id pubmed-8811128
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88111282022-02-04 Computational Screening Strategy for Drug Repurposing Identified Niclosamide as Inhibitor of Vascular Calcification Tanaka, Takeshi Asano, Takaharu Okui, Takehito Kuraoka, Shiori Singh, Sasha A. Aikawa, Masanori Aikawa, Elena Front Cardiovasc Med Cardiovascular Medicine Vascular calcification is a cardiovascular disorder with no therapeutic options. We recently reported that o-octanoyltransferase (CROT) suppression can inhibit vascular calcification in vivo and in vitro through amelioration of mitochondrial function and fatty acid metabolism. Inhibiting calcification with a small molecule compound targeting CROT-associated mechanisms will be a promising non-invasive treatment of vascular calcification. Here we used a computational approach to search for existing drugs that can inhibit vascular calcification through the CROT pathway. For screening of the compounds that reduce CROT expression, we utilized the Connectivity Map encompassing the L1000 computational platform that contains transcription profiles of various cell lines and perturbagens including small molecules. Small molecules (n = 13) were identified and tested in human primary smooth muscle cells cultured in osteogenic media to induce calcification. Niclosamide, an FDA-improved anthelmintic drug, markedly inhibited calcification along with reduced alkaline phosphatase activity and CROT mRNA expression. To validate this compound in vivo, LDL receptor (Ldlr)-deficient mice fed a high fat diet were given oral doses of niclosamide (0 or 750 ppm admixed with diet) for 10 weeks. Niclosamide treatment decreased aortic and carotid artery calcification as determined by optical near infrared molecular imaging (OsteoSense680) and histological analysis. In addition, niclosamide improved features of fatty liver, including decreased cholesterol levels along with decreased Crot expression, while plasma total cholesterol levels did not change. Proteomic analysis of aortic samples demonstrated that niclosamide affected wingless/integrated (Wnt) signaling pathway and decreased runt-related transcription factor 2 (Runx2) expression, an essential factor for calcification. Our target discovery strategy using a genetic perturbation database with existing drugs identified niclosamide, that in turn inhibited calcification in vivo and in vitro, indicating its potential for the treatment of vascular calcification. Frontiers Media S.A. 2022-01-20 /pmc/articles/PMC8811128/ /pubmed/35127876 http://dx.doi.org/10.3389/fcvm.2021.826529 Text en Copyright © 2022 Tanaka, Asano, Okui, Kuraoka, Singh, Aikawa and Aikawa. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Tanaka, Takeshi
Asano, Takaharu
Okui, Takehito
Kuraoka, Shiori
Singh, Sasha A.
Aikawa, Masanori
Aikawa, Elena
Computational Screening Strategy for Drug Repurposing Identified Niclosamide as Inhibitor of Vascular Calcification
title Computational Screening Strategy for Drug Repurposing Identified Niclosamide as Inhibitor of Vascular Calcification
title_full Computational Screening Strategy for Drug Repurposing Identified Niclosamide as Inhibitor of Vascular Calcification
title_fullStr Computational Screening Strategy for Drug Repurposing Identified Niclosamide as Inhibitor of Vascular Calcification
title_full_unstemmed Computational Screening Strategy for Drug Repurposing Identified Niclosamide as Inhibitor of Vascular Calcification
title_short Computational Screening Strategy for Drug Repurposing Identified Niclosamide as Inhibitor of Vascular Calcification
title_sort computational screening strategy for drug repurposing identified niclosamide as inhibitor of vascular calcification
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811128/
https://www.ncbi.nlm.nih.gov/pubmed/35127876
http://dx.doi.org/10.3389/fcvm.2021.826529
work_keys_str_mv AT tanakatakeshi computationalscreeningstrategyfordrugrepurposingidentifiedniclosamideasinhibitorofvascularcalcification
AT asanotakaharu computationalscreeningstrategyfordrugrepurposingidentifiedniclosamideasinhibitorofvascularcalcification
AT okuitakehito computationalscreeningstrategyfordrugrepurposingidentifiedniclosamideasinhibitorofvascularcalcification
AT kuraokashiori computationalscreeningstrategyfordrugrepurposingidentifiedniclosamideasinhibitorofvascularcalcification
AT singhsashaa computationalscreeningstrategyfordrugrepurposingidentifiedniclosamideasinhibitorofvascularcalcification
AT aikawamasanori computationalscreeningstrategyfordrugrepurposingidentifiedniclosamideasinhibitorofvascularcalcification
AT aikawaelena computationalscreeningstrategyfordrugrepurposingidentifiedniclosamideasinhibitorofvascularcalcification